Published since 1965, Laser Focus World provides comprehensive global coverage of optics, photonics, and optoelectronic technologies, applications, and markets. With 80,000+ qualified print subscribers and over a half-million annual visitors to our online content, we are the go-to source to access decision makers and stay in-the-know.

In addition to providing in-depth articles written by Laser Focus World editors, Laser Focus World accepts articles, news stories, and new product information for publication from qualified outside contributors. 

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Subscribe

A Laser Focus World newsletter subscription is free to qualified professionals. Subscribe here.

Get Published!

Laser Focus World welcomes original, bylined contributed articles for publishing, provided the material is non-commercial and runs first on our site. For consideration, contact Sally Cole Johnson ([email protected]). For more information, see our Editorial Guidelines

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics. Watch here.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community. Listen here.

Contact Us

Newsletter Archive

Magazine Archive

Meet the Laser Focus World Team

Editorial

Contact Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

SHAREHOLDER ALERT: Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against Revance Therapeutics, Inc. (RVNC) - Deadline is March 4, 2025

CLICK HERE TO JOIN THE CASE

If you are an investor in Revance and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing pmayer@kaplanfox.com or by calling (646) 315-9003.

DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than March 4, 2025 to serve as a lead plaintiff for the purported class.  If you have losses we encourage you to contact us to learn more about the lead plaintiff process.

Revance is a biotechnology company and the distributor of certain dermal filler products pursuant to an exclusive distribution agreement with Teoxane SA.

On August 12, 2024, Revance issued a press release announcing that the Company had entered into a merger agreement with Crown Laboratories (“Crown”).  Under the terms of the agreement, the press release indicated that Crown would commence a tender offer to acquire all outstanding shares of Revance’s common stock for $6.66 per share (the “Tender Offer”).

Then, on September 23, 2024, Revance disclosed that it “received a notice to remedy alleged material breaches, including breaches of the maximum levels of buffer stock and required efforts to promote and sell Teoxane products, under the Company’s exclusive distribution agreement with Teoxane SA.”  Due to the dispute with Teoxane, the Company advised that Crown’s Tender Offer had been delayed until at least October 4, 2024.

On this news, the price of Revance stock fell $.445 per share, or 7.66%, to close at $5.365 per share on September 23, 2024.

Then, on December 9, 2024, the Company disclosed that Crown and Revance had amended their merger agreement, and that Crown would commence a tender offer on December 12, 2024 to acquire all outstanding shares of Revance common stock for $3.10 per share, more than 50% lower than the original purchase price.

On this news, the price of Revance stock fell $.79 per share, or 20.68%, to close at $3.03 per share on December 9, 2024.

The complaint alleges, among other things, that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that (i) Revance was in material breach of the Distribution Agreement; (ii) the foregoing subjected the Company to an increased risk of litigation, as well as monetary and reputational harm; and (iii) all the foregoing increased the risk that the Tender Offer would be delayed and/or amended.

WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey.  With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand.  Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients.  For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

If you have any questions about this Notice, your rights, or your interests, please contact:

CONTACT:
Pamela A. Mayer
KAPLAN FOX & KILSHEIMER LLP
800 Third Avenue, 38th Floor
New York, New York 10022
(646) 315-9003
pmayer@kaplanfox.com

Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
1999 Harrison Street, Suite 1560
Oakland, California 94612
(415) 772-4704
lking@kaplanfox.com

Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client. https://www.kaplanfox.com/case/revance-therapeutics-inc/

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.